CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,430 enrolled
Drug / intervention
MDA with DHAp (Eurartesim) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02329301
NCT02329301N/ACompleted
CompareCT.gov

Assessing the Effectiveness of Mass Drug Administration (MDA) With Dihydroartemisinin + Piperaquine for Reducing Malaria Parasite Infection Prevalence and Incidence in Southern Province Zambia

PATH·interventional·Posted Dec 31, 2014·Updated Sep 16, 2020

In Brief

A clinical study evaluating MDA with DHAp (Eurartesim) and Focal MDA with DHAp (Eurartesim) for Malaria and Malaria, Falciparum. Completed, enrolled 2,430 participants across 1 site.

Detailed Summary

To quantify the relative effectiveness, cost, and cost-effectiveness of fMDA and MDA with DHAp against no mass treatment for reducing P. falciparum parasite prevalence, confirmed OPD malaria case incidence and cohort infection incidence in areas of high and low malaria transmission and in a program-relevant manner that will permit adoption and adaptation for wider-scale deployment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalaria, Malaria, Falciparum
CountriesZambia
CollaboratorsMinistry of Health, Zambia, Minister of Community Development, Mother and Child Health, Zambia, Tulane University

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 31, 2014
Enrollment StartSep 1, 2014
Primary CompletionJun 1, 2016
Study CompletionAug 1, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.5 years ago

Interventions

MDA with DHAp (Eurartesim)drug

Eurartesim is the brand name.

Focal MDA with DHAp (Eurartesim)drug

Eurartesim is the brand name.